pomp
diseas
rare
lysosom
storag
disord
incid
african
american
peopl
european
ancestri
pomp
diseas
sever
inborn
error
metabol
biallel
mutat
gaa
gene
result
decreas
absent
activ
gaa
enzym
caus
abnorm
cellular
storag
glycogen
membranebound
oppos
nonmembran
boundglycogen
seen
glycogen
storag
diseas
mitochondri
disord
pomp
diseas
includ
major
phenotyp
infantileonset
pomp
diseas
lateonset
pomp
diseas
differ
characterist
base
age
onset
organ
involv
sever
rate
progress
earlier
onset
manifest
faster
rate
progress
infantileonset
pomp
diseas
may
manifest
utero
often
diagnos
month
age
find
hypotonia
gener
muscl
weak
feed
difficulti
failur
thrive
hear
loss
hypertroph
cardiomyopathi
systol
dysfunct
respiratori
distress
feed
difficulti
may
result
facial
hypotonia
macroglossia
tongu
weak
poor
oromotor
skill
without
enzym
replac
therapi
patient
infantileonset
pomp
diseas
develop
cardiomegali
hypertroph
cardiomyopathi
progress
left
ventricular
outflow
obstruct
well
systol
diastol
dysfunct
enlarg
heart
result
diminish
lung
volum
atelectasi
sometim
bronchial
compress
progress
deposit
glycogen
result
conduct
defect
seen
shorten
pr
interv
electrocardiogram
untreat
infant
death
commonli
occur
first
year
life
cardiopulmonari
insuffici
present
case
patient
infantileonset
pomp
diseas
present
sever
hypertroph
cardiomyopathi
systol
diastol
cardiac
dysfunct
hypotonia
african
american
femal
uncompl
prenat
histori
born
week
gestat
age
via
vagin
deliveri
mother
receiv
prenat
care
late
second
trimest
took
prenat
vitamin
pregnant
deni
take
prescript
overthecount
medic
also
deni
tobacco
alcohol
drug
use
prenat
ultrasound
normal
deliveri
patient
experienc
brief
shoulder
dystocia
develop
desatur
shortli
birth
hypoton
palpabl
left
clavicl
fractur
discov
examin
lung
sound
diminish
left
transfer
neonat
intens
care
unit
nicu
manag
pediatr
cardiologist
evalu
infant
nicu
chest
xray
show
cardiomegali
initi
echocardiogram
demonstr
normal
cardiac
anatomi
normal
biventricular
systol
function
right
ventricular
hypertrophi
elev
right
ventricular
pressur
time
find
surmis
relat
placent
insuffici
caus
right
ventricular
hypertrophi
persist
elev
pulmonari
vascular
resist
plan
reevalu
patient
later
date
allow
pulmonari
vascular
resist
decreas
right
ventricl
remodel
followup
month
life
patient
echocardiogram
demonstr
new
biventricular
hypertrophi
new
moder
diminish
left
ventricular
systol
function
eject
fraction
normal
rang
time
clinic
well
good
oral
intak
start
oral
enalapril
therapi
system
afterload
reduct
four
day
later
patient
present
emerg
depart
sever
hypotonia
decreas
oral
intak
vomit
decreas
intak
vomit
thought
relat
viral
ill
patient
admit
evalu
treatment
discharg
home
week
later
patient
subsequ
genet
evalu
consist
diagnosi
pomp
diseas
low
activ
acid
alphaglucosidas
compound
heterozyg
mutat
gaa
gene
matern
patern
famili
histori
neg
pomp
diseas
full
sister
asymptomat
parent
reluct
test
gaa
mutat
parent
african
american
deni
consanguin
patient
schedul
receiv
first
enzym
replac
therapi
infus
alglucosidas
alfa
lumizym
one
week
turn
month
age
howev
schedul
day
febril
ill
appear
mild
cough
admit
inpati
floor
bronchiol
later
found
coronaviru
worsen
heart
failur
admit
pediatr
cardiolog
servic
next
month
shortli
admiss
clinic
statu
deterior
worsen
ventil
start
supplement
oxygen
eventu
transit
noninvas
positivepressur
ventil
echocardiogram
reveal
worsen
systol
function
eject
fraction
week
prior
transfer
gener
pediatr
unit
pediatr
cardiovascular
intens
care
unit
cvicu
initi
milrinon
infus
diuresi
initi
increas
pulmonari
edema
patient
coronaviru
infect
thought
resolv
wean
milrinon
attempt
fail
patient
increas
work
breath
elev
heart
rate
elev
brain
natriuret
peptid
level
also
requir
doubl
diuret
therapi
furosemid
chlorothiazid
well
digoxin
spironolacton
carvedilol
therapi
heart
failur
lowdos
aspirin
start
antiplatelet
therapi
one
week
admiss
patient
start
enzym
replac
therapi
initi
given
standard
dose
mgkg
everi
week
howev
given
sever
symptom
systol
dysfunct
frequenc
increas
weekli
start
third
dose
base
evid
studi
demonstr
increas
efficaci
higher
dose
test
crossreact
immunolog
materi
crim
statu
posit
requir
immun
modul
immun
toler
induct
lowdos
immunosuppress
methotrex
leucovorin
rescu
patient
immunoglobulin
g
igg
antibodi
titer
low
initi
enzym
replac
therapi
standard
dose
increas
result
increas
dosag
therefor
immun
modul
stop
fourth
dose
reduc
risk
infect
igg
titer
remain
low
given
respiratori
heart
failur
patient
fed
via
nasogastr
tube
initi
stay
cvicu
underw
swallow
studi
demonstr
sever
pharyng
dysphagia
silent
aspir
thin
liquid
penetr
nectarthick
liquid
recommend
speech
therapi
oral
feed
patient
subsequ
gastric
tube
placement
patient
admiss
sever
extens
discuss
held
patient
parent
extend
famili
regard
pomp
diseas
cardiomyopathi
overal
prognosi
addit
outsid
genet
consult
provid
second
opinion
counsel
famili
expect
famili
concern
place
gastric
tube
much
tracheostomi
tube
plan
discharg
heart
failur
therapi
includ
home
milrinon
infus
noninvas
positivepressur
ventil
gastrostomi
tube
feed
continu
enzym
infus
enzym
replac
therapi
infus
plan
continu
month
follow
reassess
statu
discharg
month
age
patient
systol
function
improv
dramat
figur
month
age
month
enzym
replac
therapi
wean
milrinon
without
issu
patient
wean
milrinon
enalapril
restart
next
month
patient
systol
function
continu
improv
although
ventricular
hypertrophi
remain
unchang
heart
failur
regimen
slowli
wean
display
good
growth
start
roll
month
age
sit
support
month
howev
multipl
viral
ill
period
admit
hospit
sever
skelet
muscl
weak
progress
worsen
ventil
die
age
month
cardiac
arrest
like
secondari
hypoventil
one
viral
episod
lysosom
gaa
ubiquit
enzym
catalyz
breakdown
glycogen
glucos
result
accumul
lysosom
nonlysosom
glycogen
multipl
tissu
consequ
pomp
diseas
affect
multipl
organ
system
bodi
infantileonset
pomp
diseas
gaa
enzym
activ
either
complet
nearli
complet
absent
typic
normal
activ
skin
fibroblast
infantileonset
pomp
diseas
progress
multisystem
disord
caus
hypotonia
feed
difficulti
first
year
life
diseas
affect
cardiac
skelet
smooth
muscl
pulmonari
gastrointestin
system
anterior
horn
cell
death
cardiorespiratori
failur
typic
occur
first
year
life
prior
avail
enzym
replac
therapi
gaa
recent
evid
shown
failur
product
autophagi
patient
pomp
diseas
progress
accumul
autophagosom
disrupt
contractil
apparatu
muscl
fiber
moreov
current
unknown
abnorm
subset
lysosom
interfer
recycl
autophagosom
content
lead
cardiac
skelet
muscl
damag
synthet
gaa
effect
revers
glycogen
accumul
cardiac
muscl
cell
administ
infant
pomp
diseas
use
higher
dose
enzym
replac
therapi
mgkg
weekli
vs
biweekli
like
result
greater
efficaci
improv
cardiac
function
recent
studi
demonstr
increas
effect
higher
dose
enzym
replac
therapi
infantileonset
pomp
diseas
case
et
al
demonstr
efficaci
altern
enzym
replac
therapi
regimen
high
frequenc
mgkg
weekli
high
dose
mgkg
everi
week
initi
respons
patient
experienc
declin
function
standard
enzym
replac
therapi
mgkg
everi
week
patient
demonstr
overal
trend
motor
improv
baselin
week
intens
enzym
replac
therapi
addit
patient
declin
clinic
plateau
motor
skill
show
function
improv
increas
dose
enzym
replac
therapi
author
state
increas
alglucosidas
alfa
dose
may
benefici
patient
pomp
diseas
experi
plateau
declin
motor
function
time
receiv
standard
regimen
new
safeti
concern
emerg
either
dose
regimen
van
gelder
et
al
report
data
may
suggest
dose
mgkg
weekli
vs
current
recommend
dose
mgkg
everi
week
improv
outcom
crimposit
patient
new
trial
pomp
diseas
base
gene
therapi
current
ongo
howev
treatment
sever
cardiac
diseas
remain
quit
challeng
conclus
typic
patient
infantileonset
pomp
diseas
sever
hypertroph
cardiomyopathi
respons
enzym
replac
therapi
patient
mild
hypertroph
cardiomyopathi
patient
sever
hypertroph
cardiomyopathi
despit
death
believ
heart
significantli
improv
death
relat
sequela
respiratori
infect
hypotonia
rather
cardiac
dysfunct
demonstr
efficaci
enzym
replac
therapi
patient
sever
hypertroph
cardiomyopathi
patient
eject
fraction
time
measur
use
simpson
biplan
method
age
month
patient
present
new
systol
dysfunct
worsen
biventricular
hypertrophi
month
diagnos
pomp
diseas
month
week
admit
hospit
bronchiol
worsen
heart
function
receiv
first
alglucosidas
alfa
lumizym
infus
month
discharg
home
hospit
month
month
roll
first
time
wean
milrinon
month
month
sat
support
month
patient
normal
eject
fraction
die
viral
ill
